1052 related articles for article (PubMed ID: 20665204)
1. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
2. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
3. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Garçon N; Van Mechelen M
Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich JT; Myers KR
Pharm Biotechnol; 1995; 6():495-524. PubMed ID: 7551233
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
[TBL] [Abstract][Full Text] [Related]
7. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
8. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
[TBL] [Abstract][Full Text] [Related]
10. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
[TBL] [Abstract][Full Text] [Related]
11. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
Baldridge JR; Crane RT
Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
[TBL] [Abstract][Full Text] [Related]
12. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
Alving CR
Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
15. Effect on cellular recruitment and the innate immune response by combining saponin, monophosphoryl lipid-A and Incomplete Freund's Adjuvant with Leishmania (Viannia) braziliensis antigens for a vaccine formulation.
Vitoriano-Souza J; Siqueira Mathias FA; Moreira NDD; Aguiar-Soares RDO; de Abreu Vieira PM; Teixeira-Carvalho A; Carneiro CM; Giunchetti RC; de Brito RCF; Fujiwara RT; Roatt BM; Melo MN; Reis AB
Vaccine; 2019 Nov; 37(49):7269-7279. PubMed ID: 31575491
[TBL] [Abstract][Full Text] [Related]
16. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
17. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
[TBL] [Abstract][Full Text] [Related]
18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
19. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
20. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
